Genome-wide association studies identify genetic loci for low von Willebrand factor levels

European Journal of Human Genetics

Volumn 24, Issue 7, 2016, Pages 1035-1040

  Van Loon, Janine ^a   Dehghan, Abbas ^a   Weihong, Tang ^b   Trompet, Stella ^c   McArdle, Wendy L ^d   Asselbergs, Folkert W ^e,f   Chen, Ming Huei ^g   Lopez, Lorna M ^h   Huffman, Jennifer E ^h   Leebeek, Frank W G ^a   Basu, Saonli ^b   Stott, David J ⁱ   Rumley, Ann ^j   Gansevoort, Ron T ^k   Davies, Gail ^h   Wilson, James J F ^h   Witteman, Jacqueline C M ^a   Cao, Xiting ^b   De Craen, Anton J M ^c   Bakker, Stephan J L ^k   Psaty, Bruce M ^g   Starr, John M ^h   Hofman, Albert ^a   Jukema, J Wouter ^c   Deary, Ian J ^h   Hayward, Caroline ^h   Van Der Harst, Pim ^k   Lowe, Gordon D O ⁱ   Folsom, Aaron R ^b   Strachan, David P ^j   Smith, Nicolas ^l,m,n   De Maat, Moniek P M ^a   O'Donnell, Christopher ^g   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MINNESOTA   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l UNIVERSITY OF WASHINGTON   (United States)

^m DEPARTMENT OF VETERANS AFFAIRS   (United States)

ⁿ CENTER FOR HEALTH STUDIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BINDING PROTEIN; CASPASE RECRUITMENT DOMAIN FAMILY MEMBER 10; DNA; ERYTHROCYTE MEMBRANE PROTEIN BAND 4.1 LIKE 4B; MEMBRANE PROTEIN; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR CLASS A MEMBER 5; STABILIN 5; SYNTAXIN BINDING PROTEIN 5; UBIQUITIN FOLD MODIDIER 1; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIGEN; BLOOD GROUP ABO SYSTEM; NERVE PROTEIN; PROTEIN; STXBP5 PROTEIN, HUMAN; SYNAPTOBREVIN; UFM1 PROTEIN, HUMAN; VON WILLEBRAND ANTIGEN;

ADULT; AGE; AGED; ANCESTRY GROUP; ARTICLE; BLEEDING TENDENCY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; CHROMOSOME 12P; CHROMOSOME 13Q; CHROMOSOME 6Q; CHROMOSOME 9Q; EUROPEAN; FEMALE; GENE LOCUS; GENETIC MODEL; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CAUCASIAN; GENETICS; META ANALYSIS; METABOLISM; MIDDLE AGED; VERY ELDERLY; VON WILLEBRAND DISEASE;

ABO BLOOD-GROUP SYSTEM; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; R-SNARE PROTEINS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84944936745     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2015.222     Document Type: Article

References (45)

1. Ruggeri ZM: Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105: 699-701.
2. Ruggeri ZM, Ware J: Von Willebrand factor. FASEB J 1993; 7: 308-316.
3. Nichols WL, Hultin MB, James AH et al: Von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
4. Bladbjerg EM, de Maat MP, Christensen K, Bathum L, Jespersen J, Hjelmborg J: Genetic influence on thrombotic risk markers in the elderly - A Danish twin study. J Thromb Haemost 2006; 4: 599-607.
5. Martinelli I: Von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 2005; 42: 49-55.
6. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-155.
7. Spiel AO, Gilbert JC, Jilma B: Von Willebrand factor in cardiovascular disease: Focus on acute coronary syndromes. Circulation 2008; 117: 1449-1459.
8. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G: Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 2005; 112: 3080-3087.
9. Sadler JE, Budde U, Eikenboom JC et al: Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103-2114.
10. Goodeve A, Eikenboom J, Castaman G et al: Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
11. James PD, Notley C, Hegadorn C et al: The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007; 109: 145-154.
12. Sadler JE: Low von Willebrand factor: Sometimes a risk factor and sometimes a disease. Hematol Am Soc Hematol Educ Program 2009; 1: 106-112.
13. Sanders YV, Van der Bom JG, Isaacs A et al: CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. J Thromb Haemost 2015; 13 956-966.
14. Psaty BM, O'Donnell CJ, Gudnason V et al: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet 2009; 2: 73-80.
15. Hofman A, Breteler MM, van Duijn CM et al: The Rotterdam Study: Objectives and design update. Eur J Epidemiol 2007; 22: 819-829.
16. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol 1989; 129: 687-702.
17. Dawber TR, Meadors GF, Moore FE Jr: Epidemiological approaches to heart disease: The Framingham Study. Am J Public Health Nations Health 1951; 41: 279-281.
18. Strachan DP, Rudnicka AR, Power C et al: Lifecourse influences on health among British adults: Effects of region of residence in childhood and adulthood. Int J Epidemiol 2007; 36: 522-531.
19. McQuillan R, Leutenegger AL, Abdel-Rahman R et al: Runs of homozygosity in European populations. Am J Hum Genet 2008; 83: 359-372.
20. Yang Q, Kathiresan S, Lin JP, Tofler GH, O'Donnell CJ: Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study. BMC Med Genet 2007; 8 (Suppl 1): S12.
21. Houlihan LM, Davies G, Tenesa A et al: Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet 2010; 86: 626-631.
22. Rudan I, Campbell H, Rudan P: Genetic epidemiological studies of eastern Adriatic Island isolates, Croatia: Objective and strategies. Coll Antropol 1999; 23: 531-546.
23. Hillege HL, Fidler V, Diercks GF et al: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
24. Trompet S, de Craen AJ, Postmus I et al: Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC Med Genet 2011; 12: 131.
25. Shepherd J, Blauw GJ, Murphy MB et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-1630.
26. Pare G, Chasman DI, Kellogg M et al: Novel association of ABO histo-blood group antigen with soluble ICAM-1: Results of a genome-wide association study of 6,578 women. PLoS Genet 2008; 4: E1000118.
27. Clayton D: Testing for association on the X chromosome. Biostatistics 2008; 9: 593-600.
28. Marchini J, Howie B, Myers S, McVean G, Donnelly P: A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906-913.
29. Servin B, Stephens M: Imputation-based analysis of association studies: Candidate regions and quantitative traits. PLoS Genet 2007; 3: E114.
30. Li Y, Ding J, Abecasis GR: Mach 1.0: Rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet 2006; 79: S2290.
31. Devlin B, Roeder K, Wasserman L: Genomic control, a new approach to genetic-based association studies. Theor Popul Biol 2001; 60: 155-166.
32. Gallinaro L, Cattini MG, Sztukowska M et al: A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111: 3540-3545.
33. Van Schie MC, Wieberdink RG, Koudstaal PJ et al: Genetic determinants of von Willebrand factor plasma levels and the risk of stroke: The Rotterdam Study. J Thromb Haemost 2012; 10: 550-556.
34. Desch KC, Ozel AB, Siemieniak D et al: Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci USA 2013; 110: 588-593.
35. van Schie MC, de Maat MP, Isaacs A et al: Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood 2011; 117: 1393-1399.
36. van Schie MC, van Loon JE, de Maat MP, Leebeek FW: Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: A review. J Thromb Haemost 2011; 9: 899-908.
37. Campos M, Sun W, Yu F et al: Genetic determinants of plasma von Willebrand factor antigen levels: A target gene SNP and haplotype analysis of ARIC cohort. Blood 2011; 117: 5224-5230.
38. Lowenstein CJ, Morrell CN, Yamakuchi M: Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med 2005; 15: 302-308.
39. van Loon JE, Leebeek FW, Deckers JW et al: Effect of genetic variations in syntaxinbinding protein-5 and syntaxin-2 on von Willebrand factor concentration and cardiovascular risk. Circ Cardiovasc Genet 2010; 3: 507-512.
40. Harris EN, Weigel PH: The ligand-binding profile of HARE: Hyaluronan and chondroitin sulfates A, C, and D bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology 2008; 18: 638-648.
41. Komatsu M, Chiba T, Tatsumi K et al: A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J 2004; 23: 1977-1986.
42. Daniel J, Liebau E: The ufm1 cascade. Cells 2014; 3: 627-638.
43. Azfer A, Niu J, Rogers LM, Adamski FM, Kolattukudy PE: Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. Am J Physiol Heart Circ Physiol 2006; 291: H1411-H1420.
44. Smith NL, Chen MH, Dehghan A et al: Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-1392.
45. van Loon JE, Sanders YV, de Wee EM, Kruip MJ, de Maat MP, Leebeek FW: Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients. PLoS One 2012; 7: E40624.